Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed as a multi-center, open-label, dose-escalation,
dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of
PB101 in patients with advanced solid tumors who have progressed after standard of care.
PB101 may stop the growth of tumor cells by blocking blood flow to the tumor and modulating
the tumor microenvironment.